A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Public ClinicalTrials.gov record NCT03862430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Study identification
- NCT ID
- NCT03862430
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2023
- Primary completion
- Jun 29, 2027
- Completion
- Sep 29, 2027
- Last update posted
- Aug 5, 2026
2023 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Center for Neurosciences | Tucson | Arizona | 85718 | — |
| University of Arizona | Tucson | Arizona | 85719 | — |
| UC Irvine Health- Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Providence St. John's Cancer Institute | Santa Monica | California | 90404 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| St. Francis Medical Center, OSF Healthcare | Peoria | Illinois | 61637 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Saint Luke's Cancer Institute | Kansas City | Missouri | 64111 | — |
| Atlantic Health System | Summit | New Jersey | 07901 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University Hospitals Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03862430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03862430 live on ClinicalTrials.gov.